Annual report pursuant to Section 13 and 15(d)

4. Significant Strategic Collaborations (Details Narrative)

v3.20.4
4. Significant Strategic Collaborations (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2020
Dec. 31, 2019
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue   $ 436,942 $ 17,066
Research and development expenses   1,731,406 4,889,340
Prepaid expenses and other   200,000 700,000
MSA [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Prepaid expenses and other   $ 25,000 100,000
Pharmsynthez [Member] | Series B Preferred Stock [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Warrants outstanding   1,500,000  
Takeda [Member] | Royalty Revenue [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue   $ 437,000 $ 17,000
Scripps Research [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Research and development expenses   $ 900,000  
Pharmsynthez [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Research and development expenses $ 350,000    
Percent ownership in Xenetic   5.10% 7.40%
Pharmsynthez [Member] | MSA [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Research and development expenses   $ 200,000  
Pharmsynthez [Member] | Work Order [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Milestone payment   50,000  
SynBio [Member] | Co-Development Agreement [Member] | Research, development, license and supply agreement [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue   $ 0 $ 0